RTR242: Meet the "longevity pill" developed by a startup backed by Sam Altman.

The quest to live longer and better has always been at the heart of science, but recent advances in biotechnology are transforming this ambition into something increasingly concrete. It is in this context that [the following] emerges. RTR242, developed by Retro Biosciences, startup supported by Sam altmanPresented as a potential "longevity pill," the drug's purpose is not only to treat specific diseases, but also to act directly on the cellular mechanisms linked to aging.

How the RTR242 pill works

A RTR242 It is described as a small molecule drug developed to act directly on one of the body's most fundamental mechanisms: autophagyCell regeneration is a natural process responsible for "cleaning" and recycling damaged components within cells. With aging, this function tends to lose efficiency, allowing the accumulation of cellular debris that impairs tissue function, especially in the brain.

In practice, the proposal of RTR242 é increase autophagic flowIn other words, it stimulates and accelerates this cellular recycling system. Unlike broader approaches, such as dietary changes or metabolic interventions, the compound acts in a targeted way, seeking to reactivate specific cellular pathways that regulate the degradation and reuse of defective proteins.

This mechanism gains particular relevance in neurodegenerative diseases such as Alzheimer's disease, in which there is a progressive accumulation of abnormal proteins in the brain. These proteins, often misfolded or damaged, form toxic aggregates that interfere with communication between neurons and contribute to cognitive decline.

By stimulating autophagy, the RTR242 search reduce this accumulation of cellular debrisThis allows the cells to process and eliminate these harmful structures again. The central idea is to restore a balance that, under normal conditions, would maintain a healthy cellular environment, preventing long-term damage.

Another important point is that autophagy is also linked to longevity. Studies show that processes such as fasting naturally activate this pathway, which helps explain why specific metabolic practices are associated with cellular benefits. RTR242 It attempts to replicate this effect pharmacologically, offering a more controlled and potentially accessible alternative.

In addition to its impact on the brain, increased autophagy can have systemic effects. Because the accumulation of defective proteins and damaged organelles occurs in different tissues, the action of autophagy can be a contributing factor. RTR242 In theory, it can contribute to the overall maintenance of the organism by slowing down processes associated with cellular aging.

A RTR242 This represents a new generation of therapies focused not only on treating symptoms, but on addressing the biological causes of aging and cellular degeneration. Its operation is based on the idea that by restoring the body's natural "cleaning" capacity, it is possible not only to combat specific diseases, but also to improve quality of life and life expectancy.

Human testing phase

Currently, the RTR242 is found in the call Phase 1 of clinical trials in humansThis marks the first time the compound has been administered to people outside of a laboratory setting. This stage began after the completion of previous phases such as proof of concept, preclinical studies in animals, and IND (Investigational New Drug) authorization, which officially authorizes the start of human trials. The startup responsible announced that it expected to begin this phase in... AustraliaThe country was chosen precisely because of its agile regulatory structure for initial human studies, between the end of 2025 and the beginning of 2026, with the first volunteers receiving the compound in a controlled environment.

Na Phase 1, The main objective is not yet to prove whether the pill works against aging or diseases such as Alzheimerbut rather evaluate safety, tolerability, and drug behavior in the human bodyThe tests typically involve a small number of participants, often healthy volunteers, to understand how the body absorbs, metabolizes, and eliminates the substance, as well as to identify potential side effects.

Furthermore, researchers are also beginning to define safe dosage rangesThis is an essential step to move forward to the next stages. Even if initial signs of benefit can be observed, they are not yet considered sufficient scientific evidence of efficacy. It is at this stage that the foundation for all subsequent clinical development is established, since any safety issue could completely halt the project.

After Phase 1, the drug still needs to go through other stages before reaching the market. Phase 2 It expands the number of participants and begins to investigate more directly whether the treatment actually works, in addition to adjusting ideal doses. As for... Phase 3 It involves hundreds or even thousands of patients, comparing the new drug with existing treatments or a placebo, to confirm its efficacy and safety on a large scale. Only after these steps can the substance be submitted for regulatory approval.

In Brazil, this regulatory process is primarily conducted by Anvisa (National Health Surveillance Agency), with monitoring by research ethics committees. The agency evaluates all clinical data generated in the different phases and only authorizes commercialization if there is consistent proof of safety, effectiveness and qualityEven after approval, the drug still undergoes an additional step called pharmacovigilance, in which its effects continue to be monitored in the real population.

Advances in Retro Biosciences

A Retro Biosciences It has a straightforward proposal: to treat aging as a biological problem that can be combated with science. Its positioning summarizes this ambition well in its slogan. "We are increasing healthy human life expectancy by 10 years."In practice, this means developing therapies capable of not only prolonging life, but also reducing or reversing age-related diseases.

“Curing cancer would add about three years to life expectancy, and curing heart disease, about four. Adding 10 years of healthy life to the adult population will have an even greater impact—one of the greatest achievements in the history of health.”

Joe Betts-LaCroix, CEO of Retro Biosciences, in an interview with Business Insider.

Although the RTR242 Although it is the most well-known project, it is only one among several research areas The company's strategy is to work with different technologies simultaneously, attacking aging through multiple pathways (brain, blood, and even tissue regeneration). This shows that the goal is not to rely on a single solution, but to build a comprehensive approach. complete portfolio of therapies.

“I tend to be more interested in therapies that reverse aging than in those that slow it down, because the idea of ​​'slowing down' seems like a weak sauce. (…) We have a taste for the types of therapeutic programs that we find interesting, redefining some aspect of our biology to an essentially younger age.”

Joe Betts-LaCroix, CEO of Retro Biosciences, in an interview with Business Insider.

One of these fronts is the program iMG, focused on diseases of the central nervous system. It uses iPS cell-derived microglial progenitorsThese are cells reprogrammed in the laboratory to recover lost functions in the brain. The idea is to replace or restore microglial cells, which over time cease to adequately protect the nervous system. Within this program is the RTR888, which has already passed proof of concept and is in the pre-clinical phase.

Another line is the iHSC, focused on blood disorders. In this case, the company works with hematopoietic stem cells derived from iPSCscapable of regenerating the blood system. The goal is to create "younger" and more functional cells to replace those that have lost efficiency with aging. The main candidate here is... RTR890, which has also already progressed through the proof-of-concept phase and is now in the pre-clinical phase.

In addition, the company invests in a different approach called tissue reprogrammingIn this model, rejuvenating factors are applied directly to the body via viral vectors (AAVs), with the aim of restoring aged cells. This technology is being studied for conditions such as osteoarthritis and age-related hearing loss, and is still in the proof-of-concept phase.

Partnership with Sam Altman and OpenAI

The relationship between the Retro Biosciences e Sam altman It begins even before the company is created. Altman was primarily responsible for making the project viable, investing approximately... $180M monthly to launch the startup. This investment was not only financial, but also strategic, positioning the company within an ecosystem that connects technology, artificial intelligence, and biotechnology.

The contribution of OpenAI for Retro Biosciences It goes beyond conceptual support; it directly engages in scientific development. In 2024, the two announced a collaboration focused on biotechnology that resulted in the creation of... GPT-4b micro, an artificial intelligence model specifically designed to work with biological data, such as protein sequences and complex cellular processes.

Unlike traditional models focused on text or code, the GPT-4b microphone was trained for to understand and propose modifications in biological systems...especially those related to cellular reprogramming. This includes predicting how small changes in proteins can alter cell behavior, something that, in the laboratory, would take years of trial and error. With AI, this process becomes guided by highly refined simulations and predictions.

One of the most relevant results of this partnership was the use of the model to optimize factors involved in cellular reprogramming, an essential step in "rejuvenating" aged cells. According to the data released, the system was able to propose changes that increased by up to 50 times the expression of reprogramming markersThis indicates a much greater efficiency in activating this process. In practice, this means making it more feasible to transform adult cells into younger, more functional states.

What is your opinion on medical experiments related to longevity, such as the pill? RTR242? Tell us in the comments below!

See also:

Pig iron: Retro Bio.

reviewed by Luis Antonio Costa in 26 / 03 / 26